District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Recruiting
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term eff... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Whitman Walker Health, Washington, District of Columbia
Conditions: HIV Infections, Multi-Antiviral Resistance
Register for Updates
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771
Recruiting
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/20/2023
Locations: Children's National Medical Center: Children's Research Institute, Washington, District of Columbia
Conditions: Asthma
Register for Updates
Registry of Asthma Characterization and Recruitment 3 (RACR3)
NCT05272241
Recruiting
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Gender:
All
Ages:
All
Trial Updated:
06/20/2023
Locations: Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site, Washington, District of Columbia
Conditions: Asthma
Register for Updates
Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting
NCT05176899
Recruiting
The purpose of this research is to evaluate the impact of Eko AI plus EMAS (Eko Murmur Analysis Software) on a clinician's referral decision in a real-world primary care setting. There is an additional objective of understanding patient outcomes when patients are referred for cardiology follow-up and/or echocardiogram.
Gender:
All
Ages:
50 years and above
Trial Updated:
06/20/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Murmur, Heart, Innocent Murmurs, Heart Murmurs, Pathologic Murmur
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Kaiser Permanente-Capitol Hill Medical Center, Washington, District of Columbia
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385
Recruiting
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a Dose Expansion: To investigate the safety and tolerability of DS-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: Johns Hopkins Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Triple Negative Breast Cancer, Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer
Register for Updates
mHealth for Breast Cancer Survivors With Insomnia
NCT05233800
Recruiting
The aim of this study is to determine the impact of the voice-activated smart speaker CBT-I components on insomnia symptoms among breast cancer survivors using a randomized clinical trial.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Breast Cancer Survivor, Insomnia
Register for Updates
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
NCT04091984
Recruiting
The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status was managed with Serum Creatinine SCr/estimated Glomerular Filtration Rate eGFR. This registry will compare patient management and outcomes in patients who receive Prospera (Prospera arm) to the outco... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: George Washington University Hospital, Washington, District of Columbia
Conditions: Kidney Transplant Rejection
Register for Updates
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
NCT03901807
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: George Washington University, Washington, District of Columbia
Conditions: Septic Shock, Endotoxemia
Register for Updates
SurvivorLink: Scalability of an Electronic Personal Health Record
NCT03543852
Recruiting
Previous research suggests that children and adolescents with cancer are at heightened risk of late effects that can occur months or years after cancer treatment, yet little is known about programs that increase their return for follow-up cancer care and late effects surveillance. This study will evaluate the impact of an electronic personal health record and education system, SurvivorLink, for pediatric cancer survivors and their caregivers. The researchers will develop a standardized intervent... Read More
Gender:
All
Ages:
All
Trial Updated:
06/06/2023
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Childhood Cancer
Register for Updates
DECIDE: Dyads and Families
NCT05139290
Recruiting
The purpose of this study is to design and test a decision-making program that is tailored to support adult daughters making healthcare decisions for their parents who are living with memory loss to improve the quality of life of African American families. There are two phases of this research study. The first phase will collect information by surveys and/or interviews. The surveys and interviews will ask questions about demographics (e.g., age, race/ethnicity), culture, health, family dynamics... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: Zeta Phi Beta Sorority, Inc., Washington, District of Columbia
Conditions: Dementia, Alzheimer Disease, Caregiver Burden
Register for Updates